What is it about?
This paper identifies a mathematical model that can accurately describe both how the etroliozumab drug concentration in the serum changes over time and how the pharmacological effect of the drug behave over time. This helps physicians and researchers to understand how to best treat patients with ulcerative colitis or other inflammatory bowel diseases using this biologic drug which is under the development.
Featured Image
Why is it important?
This mathematic model allows to accurately predict the pharmacological effect and drug concentration profiles of Etrolizumab when given at different dose levels and dose frequencies. This helps the researchers to best design the pivotal studies and facilitate the identification of the best option for how to treat the patients with inflammatory bowel diseases.
Perspectives
Model based drug development makes the drug development more efficient and more scientifically data driven. It also helps researchers and physicians to further understand the mechanism of action of the drug. Although this paper is very technical, but the effort will make things simpler when this model is applied to predict the outcome of pharmacological effect of the drug.
Meina Tang
Genentech, Inc
Read the Original
This page is a summary of: Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis, The Journal of Clinical Pharmacology, November 2017, Wiley,
DOI: 10.1002/jcph.1031.
You can read the full text:
Contributors
The following have contributed to this page
